Urgent nationwide recall for 1.8m eye drops that could make you go BLIND
More than 1.8 million cartons of eye drops have been recalled nationwide due to manufacturing issues that may have made the products unsterile.
Recall notices from the distributor, AvKARE, and the Food and Drug Administration (FDA) did not specify what the issue was, or the health hazards of using these eye drops.
But they state that improper manufacturing resulted in a 'lack of assurance of sterility' and 'may lead to products of unacceptable quality.'
'It is not possible to rule out patient risks resulting from use of these products,' the AvKARE notice states.
Using eye drops that are not properly sterilized can lead to serious eye infections, potentially causing temporary vision loss or even blindness.
In 2023, the CDC linked 50 infections across 11 states to eyedrops that were contaminated with an antibiotic-resistant bacteria. One patient died and several were left permanently blind.
Products subject to the recall include: Artificial Tears Ophthalmic Solution, Carboxymethylcellulose Sodium Ophthalmic Gel 1%, Carboxymethylcellulose Sodium Ophthalmic Solution, Lubricant Eye Drops Solution and Polyvinyl Alcohol Ophthalmic Solution.
The faulty drops were distributed between May 26, 2023 and April 21, 2025, and all of them appear to be for alleviating dry eye symptoms.
The FDA discovered the manufacturing issues during an audit. Their notice does not state who manufactured the drops or if they were made by a particular brand.
AvKARE, a healthcare distributor for pharmaceuticals and infection control products based in Pulaski, Tennessee, urged consumers who purchased the potentially contaminated drops to stop using them immediately.
It also stated that stores which purchased the drops should remove them from their inventory and return them to AvKARE for a full refund, which will also cover the cost of shipping them back to the distributor.
'We regret any inconvenience that this may cause,' the notice states.
It also explains that BRS Analytical Service, LLC. notified AvKARE of the voluntary recall.
BRS Analytical Service is an independent contract testing laboratory that tests pharmaceutical products to make sure they are properly manufactured and ready for distribution.
The recalled eye drops were intended to treat dry eye, which is a condition that occurs when the eyes either don't produce enough tears to keep the eye moist, or the tears they produce don't work properly.
Symptoms include irritation that feels like a gritty or sandy sensation in the eyes, stinking or burning; redness; sensitivity to light; stringy mucus in or around the eyes; blurred vision and tired eyes.
This recall comes at a time when more people may be using eye drops, as allergy season can make dry eye symptoms worse.
Using eye drops that are not properly sterilized can lead to serious eye infections, potentially causing temporary vision loss or even blindness
Allergic reactions to pollen cause inflammation in the eyes, which can reduce tear production.
Allergy medications such as antihistamines or decongestants can contribute to dry eye symptoms too.
As a result, eyedrop sales tend to increase in the spring, when the pollen count is high.
This is a Class II recall, which means use of or exposure to these drops may cause temporary or reversible health issues, but the likelihood of serious health consequences is low, according to the FDA.
At this time, it does not appear that any consumers have reported health issues related to the use of these eye drops.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
2 hours ago
- The Guardian
Monash IVF chief executive resigns after company's second embryo transplant bungle
Monash IVF boss Michael Knaap has resigned in the wake of the reproductive healthcare company's second embryo transplant bungle. In a statement to the ASX, Monash IVF said the board had accepted Knaap's resignation as chief executive officer and managing director. This week, Monash IVF admitted to a second bungled embryo implant. In April, Monash IVF revealed a woman had given birth to the child of an unrelated woman after a separate incorrect embryo transplant in Queensland. Monash IVF said in the statement on Thursday that it 'acknowledges and respects [Knaap's] decision'. 'Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and we thank him for his years of dedicated service,' the statement said. Malik Jainudeen, Monash IVF chief financial officer and company secretary, will serve as acting chief executive. Experts are now calling for national regulation of the sector, something that the health minister, Mark Butler, said would be discussed on Friday when health ministers meet in Melbourne. Currently, IVF is regulated by state and territory laws, but a more consistent, federal approach is being urged. Clinics must be licensed by the Reproductive Technology Accreditation Committee (RTAC), a subcommittee of the Fertility Society of Australia and New Zealand (FSANZ). That's the unit that carries out audits, including on some assisted reproductive technology (ART) clinics internationally. Clinics must also follow ethical guidelines from the National Health and Medical Research Council. FSANZ said in a statement about the latest Monash IVF incident that Australia's fertility care system was 'among the safest, most transparent, and tightly regulated in the world'. FSANZ president Dr Petra Wale said errors were 'exceedingly rare' although 'deeply difficult for those affected'. FSANZ has called for a nationally consistent framework for ART, and an independent statutory authority to 'strengthen oversight and trust'. It said that while the clinical standards in IVF clinics are nationally consistent, each state and territory has its own legislation. Transitioning the RTAC to an independent statutory authority would strengthen the accreditation scheme with 'the regulatory clarity and operational flexibility needed to uphold rigorous standards and respond swiftly to emerging risks', it said, while a national approach to ART would 'strengthen transparency, streamline governance, and enhance patient care across the country'. The latest audit of Australian ART facilities found 172 non-conformance reports (NCRs), but only one was 'major'. Other countries audited, including New Zealand, had higher rates of NCRs. Professor Jeremy Thompson, from the University of Adelaide, is the cofounder and chief scientific officer at Fertilis Pty Ltd. Sign up to Afternoon Update Our Australian afternoon update breaks down the key stories of the day, telling you what's happening and why it matters after newsletter promotion He said there is a global shortage of well-trained and experienced embryologists, so 'levels of training and experience can vary', and that it was a stressful job where 'skill and time management are critical for the best outcome'. But he said that 'Australia's reputation as a leader in embryology training and technique auditing is beyond question'. University of NSW associate professor Kuldip Sidhu, co-founder and director of CK Cell Technologies, said more rigorous compliance was needed in the industry. Embryologists are not currently registered under a national scheme, and doing this would 'help in adding another layer of responsibility to check such mishappenings in the IVF industry', he said. Dr Evie Kendal, a senior lecturer in health promotion at Swinburne University of Technology, said that with more human intervention in reproduction there was an increased potential for human error. 'Previous safeguards are clearly not up to the challenge of protecting clients against such incidents, and urgent ethical and policy guidance is needed to prevent such mistakes from occurring again,' she said. On Tuesday, Monash IVF told the ASX it would extend the review into the Queensland incident and start a new investigation into the Victorian one. Victorian health minister, Mary-Anne Thomas, confirmed the Victorian health regulator was also investigating. She said Monash IVF's 'clinical governance standards are not where they should be'. Monash IVF said on Tuesday that as well as the investigations it would put extra verification processes and patient confirmation safeguards in place 'over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes'.
Metro
2 hours ago
- Metro
Urgent recall for 19,000 Dr Pepper Zero Sugar cans over 'serious' health risk
More than 19,000 cans of Dr Pepper Zero Sugar have been recalled in the US over fears of 'serious adverse health consequences' to some consumers. The 19,203 cans have been recalled by Pepsi Beverages Company, which is licensed to manufacture Keurig Dr Pepper products, due to mislabeling. 'Product labeled to be Zero Sugar contains full sugar product,' states a notice published by the nation's agency tasked with ensuring food, drugs and products are safe for the public. People with diabetes and others who are sensitive to sugar could become seriously ill. The affected soda was packaged in aluminum cans and sold in packs of 12 and 24. They have the best by date of February 16, 2026, and the product code XXXXRS05165. More Trending They were shipped to three US states: Florida, Georgia and South Carolina. The company initiated a voluntary recall on May 23 of this year, but the US Food and Drug Administration (FDA) reclassified it to a Class II level on Thursday. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote', according to the FDA. The reclassification comes days after the Coca-Cola Company recalled 'limited quantities' of its Topo Chico mineral water sent to five US states over possible bacterial contamination. The affected Topo Chico bottles were sent to 40 retail locations in Arizona, Louisiana, Nevada, New Mexico and Texas. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: Urgent recall of American sweets 'unsafe to eat and not compliant with UK law' MORE: Chemical spill at explosives plant sends massive orange plume into air in Ohio MORE: Leeds General Infirmary cordoned off after suspicious package is found
The Independent
3 hours ago
- The Independent
Chancellor unveils £6bn NHS funding after health-centred spending review
Some £6 billion will be spent on speeding up testing and treatment in the NHS, Rachel Reeves has announced, after she placed the health service at the heart of Government spending plans. The Chancellor unveiled the investment, which includes new scanners, ambulances and urgent treatment centres aimed at providing an extra four million appointments in England over the next five years, after Wednesday's spending review. The funding is aimed at reducing waiting lists and reaching Labour's 'milestone' of ensuring the health service carries out 92% of routine operations within 18 weeks. In the review, Ms Reeves set out day-to-day spending across Government for the next three years, as well as plans for capital investment over the next four years. The NHS and defence were seen as the winners from the settlement, as both will see higher than average rises in public spending. This comes at cost of squeezing the budgets of other Whitehall departments and experts have warned tax rises may be needed later this year. The Chancellor and Sir Keir Starmer both sought to portray the review as a 'new phase' for the Government, following the criticism Labour has faced during its first year in power, including over cuts to winter fuel allowance. Ms Reeves claimed the NHS had been 'put on its knees' as a result of under-investment by the previous government, adding: 'We are investing in Britain's renewal, and we will turn that around.' The new £6 billion investment will come from the capital settlement for the NHS and will also help to speed up diagnoses with scans and treatment available in places such as shopping centres and high streets. The scale of day-to-day spending for the NHS is akin to an extra £29 billion a year. In a broadcast interview on Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after the boost to NHS spending. But while health and defence have benefited from the review, the Home Office, Ministry of Housing, Communities and Local Government, Department for Culture, Media and Sport, Department for Transport and Department for the Environment, Food and Rural Affairs are all in line for real-terms cuts in day-to-day spending. The Foreign Office is also in line for real-terms cuts, mainly as a result of a reduction in the overseas aid budget, which was slashed as part of the commitment to boost defence spending to 2.6% of gross domestic product – including the intelligence agencies – from 2027. Ms Reeves acknowledged 'not everyone has been able to get exactly what they want' following Cabinet squabbling over departmental budgets. She said 'every penny' of the spending increases had been funded through the tax and borrowing changes she had announced in her first budget. The Chancellor also insisted she would not need to mount another tax raid to pay for her plans, but experts warned the money for the NHS might still not be enough and the Government is under international pressure to boost defence funding further. Paul Johnson, of the Institute for Fiscal Studies, described the hospital waiting times target as 'enormously ambitious', adding: 'And on defence, it's entirely possible that an increase in the Nato spending target will mean that maintaining defence spending at 2.6% of GDP no longer cuts the mustard.' At a summit later this month Nato members will consider calls to increase spending to 3.5% on defence, with a future 1.5% on defence-related measures. Steven Millard, interim director of the NIESR economic research institute, said the Chancellor's non-negotiable fiscal rules, coupled with the 'small amount of headroom' in her spending plans, meant 'it is now almost inevitable that if she is to keep to her fiscal rules, she will have to raise taxes in the autumn budget'. Elsewhere, policing leaders warned forces may need to make deep cuts after their settlement was announced. The spending review provides more than £2 billion for forces, but ministers have acknowledged some of that 'spending power' will come from council tax hikes.
